Recombinant Human IL-17RA/IL-17R Fc Avi-tag Protein, CF

Measured by its binding ability in a functional ELISA. When Recombinant human IL-17A (7955-IL) is immobilized at 0.500 μg/mL, 100 μL/well, Biotinylated Recombinant Human IL-17RA/IL-17R Fc Chimera Avi-tag Protein (Catalog # AVI177) binds with an ED50 of 5.00-30.0 ng/mL.

2 μg/lane of Biotinylated Recombinant Human IL-17RA/IL-17R Fc Chimera Avi-tag Protein (Catalog # AVI177) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 90-100 kDa and 180-200 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-17RA/IL-17R Fc Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant human IL‑17A (Catalog # 7955-IL) is immobilized at 0.500 μg/mL, 100 μL/well, Biotinylated Recombinant Human IL‑17RA/IL‑17R Fc Chimera Avi-tag (Catalog # AVI177) binds with an ED₅₀ of 5.00-30.0 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human IL-17RA/IL-17R protein
  

  Human IL-17RA/IL-17R (Leu33-Trp320) Accession # Q96F46.2	IEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• Accession #: Q96F46.2
• N-terminal Sequence: Leu33
• Structure / Form: Disulfide-linked homodimer
  Biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 62 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 90-100 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-17RA/IL-17R Fc Avi-tag Protein, CF

• CD217 antigen
• CD217
• Cdw217
• CDw217interleukin 17 receptor
• hIL-17R
• IL-17 R
• IL-17 RA
• IL-17 receptor A
• IL17RA
• IL-17RA
• IL-17RAMGC10262
• IL17Rinterleukin-17 receptor A
• interleukin 17 receptor A

Background

IL-17 R, also known as IL-17 RA, is a 120 kDa type I transmembrane glycoprotein protein that plays a central role in inflammatory responses (1-3). Mature human IL‑17 R consists of a 288 amino acid (aa) extracellular domain, a 21 aa transmembrane segment, and a 525 aa cytoplasmic domain (4). The cytoplasmic domain contains a region homologous to the TIR domain of the TLR/IL-1 R family (5). Human IL-17 R shares 72% aa sequence identity with mouse and rat  IL-17 R.  Within the extracellular domain, it shares 18%-25% sequence identity with human IL-17 RB, C, D, and E. While the expression of IL-17 is restricted to activated T cells, IL-17 R exhibits a broad tissue distribution (4). Even in the absence of ligand, IL-17 R exists on the cell surface as a multimer (6). IL-17 R can bind IL-17 but must associate with IL-17 RC to transduce signals (7, 8). Interestingly, human IL-17 R does not appear to form productive complexes with mouse IL-17 RC (8). The IL-17 R can also signal in response to IL-17F (9). IL-17 R ligation promotes T cell activation and the production of IL-6, G-CSF, SCF, and multiple pro‑inflammatory chemokines (4, 7, 9, 10). IL-17A and IL-17F synergize with TNF-alpha in the induction of CXCL1, G-CSF, and IL-6 (9, 11). This effect requires the presence of both TNF RI and TNF RII (9). IL-17 interactions with IL-17 R also inhibit the TNF-alpha induced up-regulation of fibroblast CCL5 and VCAM-1 (11). CCL5 and VCAM-1 induced effects are differentially sensitive to blockade with IL-17 R specific antibodies, suggesting that IL-17 R triggers divergent intracellular signals (11). In vivo, IL‑17 R activity is important for increased generation of neutrophils and their recruitment to sites of inflammation (10, 12, 13). IL-17 R is required for host defense against microbial infection and for the progression of arthritis from inflammation to destructive joint erosion (10, 13). Our Avi-tag Biotinylated human IL-17R Fc chimera features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Iwakura, Y. and H. Ishigame (2006) J. Clin. Invest. 116:1218.
2. Moseley, T.A. et al. (2003) Cytokine Growth Factor Rev. 14:155.
3. Kawaguchi, M. et al. (2004) J. Allergy Clin. Immunol. 114:1265.
4. Yao, Z. et al. (1995) Immunity 3:811.
5. Novatchkova, M. et al. (2003) Trends Biochem. Sci. 28:226.
6. Kramer, J.M. et al. (2006) J. Immunol. 176:711.
7. Hymowitz, S.G. et al. (2001) EMBO J. 20:5332.
8. Toy, D. et al. (2006) J. Immunol. 177:36.
9. McAllister, F. et al. (2005) J. Immunol. 175:404.
10. Ye, P. et al. (2001) J. Exp. Med. 194:519.
11. Schnyder, B. et al. (2005) Cytokine 31:191.
12. Tan, W. et al. (2006) J. Immunol. 176:6186.
13. Lubberts, E. et al. (2005) J. Immunol. 175:3360.

Bioinformatics

• Uniprot:
  • Q96F46.2()